Tetra Bio-Pharma wins a drug license to distribute REDUVO cannabinoid soft gel capsules in Canada
The company said that the addressable market for the synthetic cannabinoid drug in Canada is pegged at around C$80 million by 2022 Armed with the drug license, Tetra said that it has now submitted a Cannabis Drug License application to Health Canada.
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, revealed that it has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO cannabinoid soft gel capsules in Canada.
REDUVO is a synthetic THC-based soft gel capsule aimed as a therapy to combat severe nausea and vomiting associated with cancer chemotherapy. It is currently being assessed by Health Canada for the issuance of a Drug Identification Number (DIN). REDUVO, known as Marinol in the United States, has been approved as a regulated pharmaceutical drug by the US Food and Dr
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
REPEAT - Pure Extracts Applauds Health Canada SAP for Psilocybin-Assisted Psychotherapy Inclusion
Pure Extracts Technologies Corp.December 15, 2020 GMT Special Access Programme Review Considered a Milestone Event Toward Mainstream Acceptance
VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, and the rapidly emerging functional mushroom sector, is pleased to support Health Canada’s proposed intent to revise the Special Access Programme (SAP) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments. The intended SAP revision, announced on December 11th, could lead to important new medical applications, particularly in the complex and growing mental health secto
VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE)
Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, and the rapidly emerging functional mushroom sector, is pleased to support Health Canada’s proposed intent to revise the Special Access Programme (SAP) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments. The intended SAP revision, announced on December 11th, could lead to important new medical applications, particularly in the complex and growing mental health sector.
Health Canada’s announcement could act as a milestone achievement driving advanced research initiatives forward. This includes several ongoing clinical trials that consistently indicate breakthrough therapy potential of psilocybin-assisted psychotherapy for a number of mental health patients suffering from conditions where conventi